Literature DB >> 35637316

Development of an efficient single-cell cloning and expansion strategy for genome edited induced pluripotent stem cells.

Nupur Bhargava1,2, Priya Thakur1,2, Thulasi Priyadharshini Muruganandam1,2, Shashank Jaitly1,2, Pragya Gupta1,2, Neelam Lohani1,2, Sangam Giri Goswami1,2, Vinodh Saravanakumar1, Saurabh Kumar Bhattacharya3, Suman Jain4, Sivaprakash Ramalingam5,6.   

Abstract

BACKGROUND: Disease-specific human induced pluripotent stem cells (hiPSCs) can be generated directly from individuals with known disease characteristics or alternatively be modified using genome editing approaches to introduce disease causing genetic mutations to study the biological response of those mutations. The genome editing procedure in hiPSCs is still inefficient, particularly when it comes to homology directed repair (HDR) of genetic mutations or targeted transgene insertion in the genome and single cell cloning of edited cells. In addition, genome editing processes also involve additional cellular stresses such as poor cell viability and genetic stability of hiPSCs. Therefore, efficient workflows are desired to increase genome editing application to hiPSC disease models and therapeutic applications. METHODS AND
RESULTS: To this end, we demonstrate an efficient workflow for feeder-free single cell clone generation and expansion in both CRISPR-mediated knock-out (KO) and knock-in (KI) hiPSC lines. Using StemFlex medium and CloneR supplement in conjunction with Matrigel cell culture matrix, we show that cell viability and expansion during single-cell cloning in edited and unedited cells is significantly enhanced. Keeping all factors into account, we have successfully achieved hiPSC single-cell survival and cloning in both edited and unedited cells with rates as maximum as 70% in less than 2 weeks.
CONCLUSION: This simplified and efficient workflow will allow for a new level of sophistication in generating hiPSC-based disease models to promote rapid advancement in basic research and also the development of novel cellular therapeutics.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Disease modeling; Drug discovery; Genome-editing; Induced pluripotent stem cells; Regenerative medicine; Single-cell cloning

Mesh:

Year:  2022        PMID: 35637316     DOI: 10.1007/s11033-022-07621-9

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  16 in total

1.  Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture.

Authors:  M Amit; M K Carpenter; M S Inokuma; C P Chiu; C P Harris; M A Waknitz; J Itskovitz-Eldor; J A Thomson
Journal:  Dev Biol       Date:  2000-11-15       Impact factor: 3.582

2.  Karyotype of human ES cells during extended culture.

Authors:  Jeremy J Buzzard; Nicholas M Gough; Jeremy M Crook; Alan Colman
Journal:  Nat Biotechnol       Date:  2004-04       Impact factor: 54.908

3.  Generation and characterization of induced pluripotent stem cell line (IGIBi001-A) from a sickle cell anemia patient with homozygous β-globin mutation.

Authors:  Nupur Bhargava; Shashank Jaitly; Sangam Giri Goswami; Suman Jain; Debojyoti Chakraborty; Sivaprakash Ramalingam
Journal:  Stem Cell Res       Date:  2019-06-14       Impact factor: 2.020

4.  Improving single-cell cloning workflow for gene editing in human pluripotent stem cells.

Authors:  Yi-Hsien Chen; Shondra M Pruett-Miller
Journal:  Stem Cell Res       Date:  2018-08-04       Impact factor: 2.020

Review 5.  Programmable Site-Specific Nucleases for Targeted Genome Engineering in Higher Eukaryotes.

Authors:  Ganesan Govindan; Sivaprakash Ramalingam
Journal:  J Cell Physiol       Date:  2016-03-15       Impact factor: 6.384

Review 6.  Induced pluripotent stem cells in disease modelling and drug discovery.

Authors:  R Grant Rowe; George Q Daley
Journal:  Nat Rev Genet       Date:  2019-07       Impact factor: 53.242

7.  CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response.

Authors:  Karol Szlachta; Cem Kuscu; Turan Tufan; Sara J Adair; Stephen Shang; Alex D Michaels; Matthew G Mullen; Natasha Lopes Fischer; Jiekun Yang; Limin Liu; Prasad Trivedi; Edward B Stelow; P Todd Stukenberg; J Thomas Parsons; Todd W Bauer; Mazhar Adli
Journal:  Nat Commun       Date:  2018-10-15       Impact factor: 14.919

Review 8.  The Hippo Signaling Pathway in Cardiac Development and Diseases.

Authors:  Masum M Mia; Manvendra K Singh
Journal:  Front Cell Dev Biol       Date:  2019-10-01

9.  Genetic screens in isogenic mammalian cell lines without single cell cloning.

Authors:  Peter C DeWeirdt; Annabel K Sangree; Ruth E Hanna; Kendall R Sanson; Mudra Hegde; Christine Strand; Nicole S Persky; John G Doench
Journal:  Nat Commun       Date:  2020-02-06       Impact factor: 14.919

10.  A human isogenic iPSC-derived cell line panel identifies major regulators of aberrant astrocyte proliferation in Down syndrome.

Authors:  Keiji Kawatani; Toshihiko Nambara; Nobutoshi Nawa; Hidetaka Yoshimatsu; Haruna Kusakabe; Katsuya Hirata; Akira Tanave; Kenta Sumiyama; Kimihiko Banno; Hidetoshi Taniguchi; Hitomi Arahori; Keiichi Ozono; Yasuji Kitabatake
Journal:  Commun Biol       Date:  2021-06-14
View more
  1 in total

1.  Podocytes derived from human induced pluripotent stem cells: characterization, comparison, and modeling of diabetic kidney disease.

Authors:  Julie Bejoy; Justin M Farry; Jennifer L Peek; Mariana C Cabatu; Felisha M Williams; Richard C Welch; Eddie S Qian; Lauren E Woodard
Journal:  Stem Cell Res Ther       Date:  2022-07-26       Impact factor: 8.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.